Lindbrook Capital LLC Sells 951 Shares of Sanofi (NASDAQ:SNY)

Lindbrook Capital LLC trimmed its stake in Sanofi (NASDAQ:SNY) by 18.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,206 shares of the company’s stock after selling 951 shares during the period. Lindbrook Capital LLC’s holdings in Sanofi were worth $209,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Rise Advisors LLC grew its stake in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. bought a new stake in Sanofi during the fourth quarter worth about $27,000. Venturi Wealth Management LLC grew its holdings in Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA increased its stake in shares of Sanofi by 115.6% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after purchasing an additional 400 shares in the last quarter. Finally, CNB Bank purchased a new position in shares of Sanofi during the third quarter valued at approximately $39,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SNY shares. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley started coverage on Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target for the company. Finally, TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $55.00.

Sanofi Stock Up 1.8 %

Sanofi stock opened at $47.15 on Tuesday. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The stock has a fifty day simple moving average of $47.54 and a two-hundred day simple moving average of $48.50. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a market cap of $119.27 billion, a price-to-earnings ratio of 19.98, a PEG ratio of 1.62 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. Equities analysts predict that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is currently 58.47%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.